HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 years of market exclusivity and development incentives if approved. Sovleplenib is an oral spleen tyrosine kinase inhibitor currently under regulatory review in China for ITP and autoimmune hemolytic anemia, supported by positive clinical trial data. The designation highlights sovleplenib's potential to address unmet medical needs in ITP, a condition with limited effective treatments and significant patient impact.
HUTCHMED's sovleplenib gains US FDA orphan drug designation, highlighting its potential in treating primary immune thrombocytopenia. For readers following the Health sector, here is Pluang's market snapshot as of Oct 29, 2026 05:12 WIB: out of 150 priced US Health stocks, 103 rose and 46 fell. Notable movers include TDOC at USD 7.49 (+16.12%, typical hold time 39 days), SLS at USD 10.36 (-14.87%, typical hold time 7 days), and TWST at USD 172.58 (+7.96%, typical hold time 27 days, Pluang order activity 51% Sell / 49% Buy).
China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...
LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...
Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...
Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...
The global mobile battery market, valued at $24.9 billion in 2025, is projected to grow to $45.95 billion by 2035, driven by rising smartphone adoption, 5G rollout, and demand for longer-lasting, fast-charging batteries. Lithium-ion batteries dominat...
